Literature DB >> 12451985

Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.

Zhong-ping Chen1, Areti Malapetsa, Anne Monks, Timothy G Myers, Gérard Mohr, Edward A Sausville, Dominic A Scudiero, Lawrence C Panasci.   

Abstract

BACKGROUND &
OBJECTIVE: Nucleotide excision repair (NER) is a multi-enzyme DNA repair system in eukaryotes. Several NER genes in this system including XPA, XPB, ERCC1, and ERCC2 (XPD) have been implicated in anticancer drug resistance in human tumor cells. This study was designed to investigate the relationship between the expression of NER protein and the drug-resistance of human tumor cell lines.
METHODS: In this study, The authors assessed the levels of the above mentioned proteins, by utilizing Western blot analysis, in the USA National Cancer Institute (NCI) panel of 60 human tumor cell lines and correlated to the cytotoxicity patterns of 170 compounds that constitute the standard agent (SA) database.
RESULTS: The ERCC1, XPB, and XPD protein expression patterns yielded significant negative Pearson correlations with 13, 17, and 32 out of the 170 compounds, respectively (P < 0.05). XPA produced a random assortment of negative and positive correlations and did not appear to confer an overall resistance or sensitivity to these drugs. Protein expression was also compared with a pre-defined categorisation of the standard agents into six mechanism-of-action (MOA) groups resulting in an inverse association between XPD and alkylating agent sensitivity.
CONCLUSION: Our present data demonstrate that XPD protein levels correlate with resistance to alkylating agents in human tumor cell lines, suggesting that XPD plays an important role in the development of this resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451985

Source DB:  PubMed          Journal:  Ai Zheng


  4 in total

1.  Lack of association between XPC Lys939Gln polymorphism and prostate cancer risk: an updated meta-analysis based on 3039 cases and 3253 controls.

Authors:  Haoran Wu; Zhong Lv; Xugang Wang; Liang Zhang; Naixin Mo
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.

Authors:  Zhi-Kun Qiu; Dong Shen; Yin-Sheng Chen; Qun-Ying Yang; Cheng-Cheng Guo; Bing-Hong Feng; Zhong-Ping Chen
Journal:  Chin J Cancer       Date:  2013-08-06

3.  Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.

Authors:  Sandra G Boccard; Sandie V Marand; Sandra Geraci; Laurie Pycroft; François R Berger; Laurent A Pelletier
Journal:  Oncotarget       Date:  2015-10-06

4.  XPC exon15 Lys939Gln variant increase susceptibility to prostate adenocarcinoma: Evidence based on 4306 patients and 4779 controls.

Authors:  Feng Qin; Sheng-Lin Gao; Kai Xu; Quan-Xin Su; Ze Zhang; Li Shi; Li-Jie Zhu; Li-Feng Zhang; Li Zuo
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.